Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions

Sang Hoon Ahn, Henry L.Y. Chan, Pei Jer Chen, Jun Cheng, Mahesh K. Goenka, Jinlin Hou, Seng Gee Lim, Masao Omata, Teerha Piratvisuth, Qing Xie, Hyung Joon Yim, Man Fung Yuen

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Recent guidelines of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver 2008 update of the "Asian-Pacific consensus statement on the management of chronic hepatitis B" offer comprehensive recommendations for the general management of chronic hepatitis B (CHB). These recommendations highlight preferred approaches to the prevention, diagnosis, and treatment of CHB. Nonetheless, the results of recent studies have led to an improved understanding of the disease and a belief that current recommendations on specific therapeutic considerations, including CHB treatment initiation and cessation criteria, particularly in patient populations with special circumstances, can be improved. Twelve experts from the Asia-Pacific region formed the Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B (APPROACH) Working Group to review, challenge, and assess relevant new data and inform future updates of CHB treatment guidelines. The significance of and controversy about reported findings were discussed and debated in an expert meeting of the Working Group in Beijing, China, in November 2008. This review paper attempts to identify areas requiring improved CHB management and provide suggestions for future guideline updates, with special emphasis on treatment initiation and duration.

Original languageEnglish
Pages (from-to)386-395
Number of pages10
JournalHepatology International
Volume4
Issue number1
DOIs
Publication statusPublished - 2010 Jan 1

Fingerprint

Chronic Hepatitis B
Guidelines
Withholding Treatment
Group Processes
Therapeutics
Direction compound
China
Consensus
Liver
Population

Keywords

  • ALT
  • Chronic hepatitis B (CHB)
  • HBV DNA
  • Hepatitis B virus (HBV)
  • Interferon alfa
  • Nucleoside/nucleotide analog

ASJC Scopus subject areas

  • Hepatology

Cite this

Ahn, S. H., Chan, H. L. Y., Chen, P. J., Cheng, J., Goenka, M. K., Hou, J., ... Yuen, M. F. (2010). Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions. Hepatology International, 4(1), 386-395. https://doi.org/10.1007/s12072-010-9163-9

Chronic hepatitis B : Whom to treat and for how long? Propositions, challenges, and future directions. / Ahn, Sang Hoon; Chan, Henry L.Y.; Chen, Pei Jer; Cheng, Jun; Goenka, Mahesh K.; Hou, Jinlin; Lim, Seng Gee; Omata, Masao; Piratvisuth, Teerha; Xie, Qing; Yim, Hyung Joon; Yuen, Man Fung.

In: Hepatology International, Vol. 4, No. 1, 01.01.2010, p. 386-395.

Research output: Contribution to journalReview article

Ahn, SH, Chan, HLY, Chen, PJ, Cheng, J, Goenka, MK, Hou, J, Lim, SG, Omata, M, Piratvisuth, T, Xie, Q, Yim, HJ & Yuen, MF 2010, 'Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions', Hepatology International, vol. 4, no. 1, pp. 386-395. https://doi.org/10.1007/s12072-010-9163-9
Ahn, Sang Hoon ; Chan, Henry L.Y. ; Chen, Pei Jer ; Cheng, Jun ; Goenka, Mahesh K. ; Hou, Jinlin ; Lim, Seng Gee ; Omata, Masao ; Piratvisuth, Teerha ; Xie, Qing ; Yim, Hyung Joon ; Yuen, Man Fung. / Chronic hepatitis B : Whom to treat and for how long? Propositions, challenges, and future directions. In: Hepatology International. 2010 ; Vol. 4, No. 1. pp. 386-395.
@article{f5467c8d14bd4036afa3d11c5b1e2ea5,
title = "Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions",
abstract = "Recent guidelines of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver 2008 update of the {"}Asian-Pacific consensus statement on the management of chronic hepatitis B{"} offer comprehensive recommendations for the general management of chronic hepatitis B (CHB). These recommendations highlight preferred approaches to the prevention, diagnosis, and treatment of CHB. Nonetheless, the results of recent studies have led to an improved understanding of the disease and a belief that current recommendations on specific therapeutic considerations, including CHB treatment initiation and cessation criteria, particularly in patient populations with special circumstances, can be improved. Twelve experts from the Asia-Pacific region formed the Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B (APPROACH) Working Group to review, challenge, and assess relevant new data and inform future updates of CHB treatment guidelines. The significance of and controversy about reported findings were discussed and debated in an expert meeting of the Working Group in Beijing, China, in November 2008. This review paper attempts to identify areas requiring improved CHB management and provide suggestions for future guideline updates, with special emphasis on treatment initiation and duration.",
keywords = "ALT, Chronic hepatitis B (CHB), HBV DNA, Hepatitis B virus (HBV), Interferon alfa, Nucleoside/nucleotide analog",
author = "Ahn, {Sang Hoon} and Chan, {Henry L.Y.} and Chen, {Pei Jer} and Jun Cheng and Goenka, {Mahesh K.} and Jinlin Hou and Lim, {Seng Gee} and Masao Omata and Teerha Piratvisuth and Qing Xie and Yim, {Hyung Joon} and Yuen, {Man Fung}",
year = "2010",
month = "1",
day = "1",
doi = "10.1007/s12072-010-9163-9",
language = "English",
volume = "4",
pages = "386--395",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Chronic hepatitis B

T2 - Whom to treat and for how long? Propositions, challenges, and future directions

AU - Ahn, Sang Hoon

AU - Chan, Henry L.Y.

AU - Chen, Pei Jer

AU - Cheng, Jun

AU - Goenka, Mahesh K.

AU - Hou, Jinlin

AU - Lim, Seng Gee

AU - Omata, Masao

AU - Piratvisuth, Teerha

AU - Xie, Qing

AU - Yim, Hyung Joon

AU - Yuen, Man Fung

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Recent guidelines of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver 2008 update of the "Asian-Pacific consensus statement on the management of chronic hepatitis B" offer comprehensive recommendations for the general management of chronic hepatitis B (CHB). These recommendations highlight preferred approaches to the prevention, diagnosis, and treatment of CHB. Nonetheless, the results of recent studies have led to an improved understanding of the disease and a belief that current recommendations on specific therapeutic considerations, including CHB treatment initiation and cessation criteria, particularly in patient populations with special circumstances, can be improved. Twelve experts from the Asia-Pacific region formed the Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B (APPROACH) Working Group to review, challenge, and assess relevant new data and inform future updates of CHB treatment guidelines. The significance of and controversy about reported findings were discussed and debated in an expert meeting of the Working Group in Beijing, China, in November 2008. This review paper attempts to identify areas requiring improved CHB management and provide suggestions for future guideline updates, with special emphasis on treatment initiation and duration.

AB - Recent guidelines of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver 2008 update of the "Asian-Pacific consensus statement on the management of chronic hepatitis B" offer comprehensive recommendations for the general management of chronic hepatitis B (CHB). These recommendations highlight preferred approaches to the prevention, diagnosis, and treatment of CHB. Nonetheless, the results of recent studies have led to an improved understanding of the disease and a belief that current recommendations on specific therapeutic considerations, including CHB treatment initiation and cessation criteria, particularly in patient populations with special circumstances, can be improved. Twelve experts from the Asia-Pacific region formed the Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B (APPROACH) Working Group to review, challenge, and assess relevant new data and inform future updates of CHB treatment guidelines. The significance of and controversy about reported findings were discussed and debated in an expert meeting of the Working Group in Beijing, China, in November 2008. This review paper attempts to identify areas requiring improved CHB management and provide suggestions for future guideline updates, with special emphasis on treatment initiation and duration.

KW - ALT

KW - Chronic hepatitis B (CHB)

KW - HBV DNA

KW - Hepatitis B virus (HBV)

KW - Interferon alfa

KW - Nucleoside/nucleotide analog

UR - http://www.scopus.com/inward/record.url?scp=84984538817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984538817&partnerID=8YFLogxK

U2 - 10.1007/s12072-010-9163-9

DO - 10.1007/s12072-010-9163-9

M3 - Review article

AN - SCOPUS:84984538817

VL - 4

SP - 386

EP - 395

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

IS - 1

ER -